This review highlights the 2009 ESC/ERS guidelines for managing pulmonary hypertension, emphasizing the specific diagnostic and therapeutic considerations for patients with connective tissue disease-associated PAH.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to screen systemic sclerosis patients for PAH; extends 2009 guidelines but leaves optimal regimens open for prospective study.
Pulmonary hypertension was defined as mean pulmonary artery pressure ≥ 25 mmHg at the 4th World Symposium on Pulmonary Hypertension. In 2009, the European Society of Cardiology and European Respiratory Society jointly created guidelines for practical pulmonary hypertension classifications and treatments based on the discussions at the 4th World Symposium. This classification is characterized by division into five groups: Pulmonary arterial hypertension (PAH); Pulmonary hypertension due to left heart disease; Pulmonary hypertension due to lung disease and/or hypoxia; Chronic thromboembolic pulmonary hypertension; and Pulmonary hypertension with unclear and/or multifactorial mechanisms. PAH is a common and fatal complication of connective tissue disease (CTD), but pulmonary hypertension in CTD consists of PAH, pulmonary hypertension caused by myocardial involvement, pulmonary veno-occlusive disorder, pulmonary hypertension due to interstitial lung disease. PAH has been studied widely in SSc and the estimated prevalence of 7-12%. Treatment of CTD associated PAH (CTD-PAH) consists of general therapeutic options and specific treatment. Specific treatment of CTD-PAH patients is targeted to produce vasodilatation. Calcium channel blockers (CCBs) are indicated in cases where a sufficient decrease in pulmonary arterial pressure is seen in vasoreactivity testing. If vasoreactivity is absent in CTD-PAH patients, the treatment consists of the endothelin receptor antagonists, the prostacyclin analogues and phosphodiesterase-type 5 inhibitors. Few data are available to support the use of immunosuppression in CTD-PAH. However, some case reports suggested that a minority of CTD-PAH patients could benefit from immunosuppressive therapy. The treatment of CTD-PAH patients may differ from the treatment of idiopathic PAH.
No takes yet. Share an insight, caveat, or question.
Norifumi Nakanishi (2011) conducted a review in Pulmonary hypertension and connective tissue disease. Connective tissue disease-associated pulmonary arterial hypertension has an estimated prevalence of 7-12% in systemic sclerosis and requires specific targeted treatments such as vasodilators.
Synapse has enriched 10 related papers. Consider them for comparative context: